Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: Clinical Trials

51 completed, 35 recruiting, 11 terminated, 11 unknown. 31 Phase 3, 28 Phase 2, 17 Not applicable, 8 Phase 1, 5 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	31	Completed 15, Recruiting 9, Not yet recruiting 2, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Unknown 1
Phase 2	28	Completed 11, Recruiting 5, Terminated 4, Withdrawn 3, Active not recruiting 2, Not yet recruiting 2, Unknown 1
Not applicable	17	Completed 7, Unknown 3, Active not recruiting 2, Terminated 2, Enrolling by invitation 1, Recruiting 1, Withdrawn 1
Phase 1	8	Recruiting 5, Completed 1, Not yet recruiting 1, Terminated 1
Early Phase 1	5	Recruiting 3, Completed 1, Not yet recruiting 1
Phase 4	4	Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1

Follow Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: new trials by email Literature Review of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials Research Report on Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France Genetic and Inflammatory Polyneuropathies		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1000	2026-11-01	2026-10-01
Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy Xsens motion suit - CIDP - Chronic Inflammatory Demyelinating Polyneuropathy		Recruiting	Heinrich-Heine University, Duesseldorf	50	2026-10-23	2026-10-27
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy	Phase 3	Recruiting	Kedrion S.p.A.	161	2026-10-01	2026-09-11
Ultrasound-driven Stratification in CIDP Refractory CIDP, Standard-of-care treatment for CIDP - CIDP, Chronic Inflammation		Not yet recruiting	Centre Hospitalier Universitaire de Nice	30	2026-09-01	2026-07-22
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)	Phase 2 / Phase 3	Not yet recruiting	argenx	6	2026-09-01	2026-06-10
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β	Phase 1 / Phase 2	Not yet recruiting	Zhongming Qiu	24	2026-07-15	2026-07-10
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis	Phase 1	Recruiting	Kite, A Gilead Company	57	2026-04-10	2026-10-19
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)	Phase 3	Recruiting	Grifols Therapeutics LLC	40	2026-04-02	2026-10-09
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)	Phase 1	Recruiting	Tongji Hospital	6	2026-04-01	2026-05-12
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease Whole-body Electrical Muscle Stimulation Exercise - Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis	Not applicable	Recruiting	University of Missouri-Columbia	50	2026-03-10	2026-03-17
Tongji NADs Cohort No active interventions - Multiple Sclerosis, NMO Spectrum Disorder		Not yet recruiting	Tongji Hospital	1550	2026-03-01	2026-01-21
Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices CIDP - Chronic Inflammatory Demyelinating Polyneuropathy		Recruiting	Heinrich-Heine University, Duesseldorf	35	2026-01-15	2026-06-10
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning - Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG)	Early Phase 1	Recruiting	Tongji Hospital	36	2025-12-12	2026-05-12
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy Conventional Therapy, Telitacicept - Refractory Chronic Inflammatory Demyelinating Polyneuropathy	Not applicable	Active not recruiting	Sichuan Academy of Medical Sciences	76	2025-09-26	2026-05-19
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP	Phase 3	Recruiting	argenx	160	2025-09-16	2026-10-27
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. Assistive gait devices combined with physiotherapy - Inclusion Body Myositis, Myotonic Dystrophy 1	Not applicable	Enrolling by invitation	LMU Klinikum	30	2025-09-01	2025-07-18
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy	Phase 2	Terminated	Immunovant Sciences GmbH	26	2025-08-28	2026-08-11
Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic Inflammatory Demyelinating Polyneuropathy		Recruiting	University of Ulm	140	2025-08-27	2025-09-11
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP	Phase 3	Recruiting	argenx	218	2025-08-22	2026-10-16
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP		Recruiting	argenx	200	2025-08-11	2026-10-23

Showing 20 of 136. Sign in to see all of them.

Narrower conditions

Myasthenia Gravis (14)  ·  Guillain-Barre Syndrome (12)  ·  Autoimmune Diseases of the Nervous System (11)  ·  Multiple Sclerosis (11)  ·  Neuromyelitis Optica (11)  ·  Autoimmune Diseases (9)  ·  Charcot-Marie-Tooth Disease (9)  ·  Peripheral Nervous System Diseases (9)  ·  Myositis (6)  ·  Rare Diseases (6)  ·  Neuromuscular Diseases (5)  ·  Lambert-Eaton Myasthenic Syndrome (4)  ·  Muscular Atrophy, Spinal (4)  ·  Muscular Dystrophy, Facioscapulohumeral (4)

Broader conditions

Chronic Disease (136)  ·  Disease Attributes (136)  ·  Pathologic Processes (136)  ·  Pathological Conditions, Signs and Symptoms (136)  ·  Demyelinating Diseases (133)  ·  Immune System Diseases (133)  ·  Nervous System Diseases (132)  ·  Polyneuropathies (132)  ·  Polyradiculoneuropathy (132)  ·  Neuromuscular Diseases (131)  ·  Autoimmune Diseases (127)  ·  Peripheral Nervous System Diseases (127)  ·  Autoimmune Diseases of the Nervous System (125)  ·  Neurodegenerative Diseases (24)  ·  Neoplasms (16)

Interventions

Immunoglobulins, Intravenous (14)  ·  Immunoglobulins (7)  ·  Hizentra (6)  ·  Rituximab (5)  ·  Cyclophosphamide (4)  ·  fludarabine (3)  ·  gamma-Globulins (3)  ·  rozanolixizumab (3)  ·  Blood Specimen Collection (2)  ·  Injections, Subcutaneous (2)  ·  Prednisone (2)  ·  Saline Solution (2)  ·  Solutions (2)  ·  efgartigimod alfa (2)  ·  Administration, Intravenous (1)

Sponsors

argenx (9)  ·  University of Aarhus (6)  ·  CSL Behring (5)  ·  Takeda (5)  ·  Tongji Hospital (5)  ·  Sanofi (4)  ·  Centre Hospitalier Universitaire de Nice (3)  ·  Heinrich-Heine University, Duesseldorf (3)  ·  Immunovant Sciences GmbH (3)  ·  Istituto Clinico Humanitas (3)  ·  National Center for Research Resources (NCRR) (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Assiut University (2)  ·  Baxalta now part of Shire (2)  ·  Centre Hospitalier Universitaire de Nīmes (2)

Countries

United States (54)  ·  France (38)  ·  Germany (35)  ·  Italy (28)  ·  Denmark (24)  ·  Spain (23)  ·  United Kingdom (23)  ·  Poland (20)  ·  China (19)  ·  Canada (18)  ·  Czechia (16)  ·  Japan (16)  ·  Belgium (15)  ·  Netherlands (15)  ·  Argentina (14)

Top investigators

Alex Martino Cinnera, PhD (1)  ·  Allan Ropper, MD (1)  ·  Anthony J Windebank, MD (1)  ·  Anthony J. Windebank (1)  ·  Ari Breiner, MD, FRCPC (1)  ·  Britt S Pedersen (1)  ·  Chuan Qin (1)  ·  Chuan Qin, Prof. (1)

Results publications

PMID 42578463, PMID 18178525, PMID 38353301, PMID 38729747, PMID 12084892, PMID 12437775, PMID 12959218, PMID 14610153, PMID 15607214, PMID 15703014, PMID 16267188, PMID 16293415, PMID 16365632, PMID 16380614, PMID 16849828, PMID 16900450, PMID 19260050, PMID 19365055, PMID 19496628, PMID 19496683, PMID 19564582, PMID 19691533, PMID 20456730, PMID 20457948, PMID 20647554, PMID 20837852, PMID 22003934, PMID 23568718, PMID 23781960, PMID 24379104, PMID 24858016, PMID 27241239, PMID 27455854, PMID 27918219, PMID 28168524, PMID 28572784, PMID 28594116, PMID 28768822, PMID 28881389, PMID 28894082, PMID 29122523, PMID 29260006, PMID 30001923, PMID 30463240, PMID 30679041, PMID 31072742, PMID 31354737, PMID 32051341, PMID 32373047, PMID 32594300

NIH funding

2018 (3), 2023 (3), 2016 (2), 2019 (2), 2025 (2), 2009 (1), 2014 (1)